JPRN-UMIN000000499已完成3 期
Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary - Phase III Trial of (TC) Therapy versus (CPT-P) Therapy for Clear Cell Carcinoma of the Ovary
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 662
研究概览
简要总结
The results from the final analysis did not show a marked difference in both PFS and OS between the patients who received the [standard treatment] and those whoreceived the [experimental treatment]. - The characteristics of side effect of these two treatments differ significantly.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) Patients with a current diagnosis of epithelial ovarian tumor of low malignant potential 2) Patients with other malignancies including synchronous primary endometrial cancer or a past history of primary endometrial cancer 3) Patients who have received prior chemotherapy or radiation therapy to treat the current disease 4) Patients who received intraperitoneal chemotherapy at the time of operation 5) Patients with a prior diagnosis of malignancy are not eligible. Exceptions are: - stage 0 endometrial cancer - carcinoma in situ of the cervix - non-melanoma skin cancer - other malignancies curatively treated and > 5 years without evidence of recurrence 6) Patients who have received prior radiotherapy Exceptions Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than 5 years prior to registration, and the patient remains free of recurrent or metastatic disease. 7) Patients who have received prior chemotherapy. Exceptions Patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than 5 years prior to registration, and that the patient remains free of recurrent or metastatic disease. 8,9,10) Patients with diarrhea greater than CTCAE grade1, active infection that requires antibiotics, ongoing gastrointestinal bleeding requiring blood product support 11) Patients with unstable angina or those who have had a myocardial infarction within the past six months. Patients with evidence of abnormal cardiac conduction are eligible if their disease has been stable for the past six months. 12,13,14,16) Patients with bowel obstruction, interstitial pneumonitis, massive pleural effusion and/or ascites, known hypersensitivity to polyoxyethylated castor oil or any of four chemotherapeutic agents 15,17,18) Patients who are under treatment with Atazanavir, pregnant or lactating, would not permit completion of study or required follow-up.
研究者
相似试验
终止
不适用
A phase III clinical study to compare paclitaxel (Genexol®-PM) in combination with standard therapy (gemcitabine/cisplatin) and standard therapy alone (gemcitabine/cisplatin) in patients with advanced biliary tractNeoplasmsKCT0003726Asan Medical Center220
招募中
3 期
A study comparing two chemotherapy regimens prior to surgery for patients with technically unresectable oral cancersCTRI/2023/02/049406one
尚未招募
3 期
Study of Different types of chemotherapy in oral cancersCTRI/2023/08/056693TMC Research Administrative Council
终止
3 期
A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast CancerBreast CancerNCT01200212German Breast Group432
已完成
3 期
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal CarcinomaEsophageal Squamous Cell CarcinomaNCT01591135Fudan University436